The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Comprehensive genomic characterization of CTCs in multiple myeloma
In this interview, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the genomic characterization of circulating tumor cells (CTCs) in multiple myeloma (MM). A novel whole-genome sequencing (WGS)-based clinical assay has been developed that can enable comprehensive profiling of the myeloma cancer genome and allow for early detection of genetic alterations that confer resistance to therapy. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
